Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
382,383 The FAKTION phase 2 trial indicates that the AKT inhibitor capivasertib combined with fulvestrant significantly improves PFS and OS in postmenopausal women with HR+/HER2 advanced breast cancer who have previously received aromatase inhibitors therapy, particularly In the AKT pathway abnormal subgroup
are convalescent and feel tired, exhausted and are out of strength
Current Biology, 2012
Months 4-6: single maintenance session at month four or five
Savitz J, Drevets WC, Smith CM, Victor TA, Wurfel BE, Bellgowan PSF, et al
Human Trx and GSH systems have compensatory activities so that inhibition of one arm can be supplemented by the other 60 , suggesting that the inhibition of hTrxR by some of the compounds presented here will not be detrimental for humans as it is for schistosomes
US$ 22.87
US$ 25.40
US$ 22.18
US$ 21.37
US$ 25.63
US$ 28.79
US$ 27.76
US$ 27.12
